Psoriatic Arthritis News

The emergence of drugs inhibiting the JAK-STAT pathway has culminated in tyrosine kinase 2 inhibitors targeting psoriatic arthritis, lupus and other indications, noted a presenter at the 2022 Association of Women in Rheumatology conference.

LOUISVILLE, Ky. — Persistent, chronic inflammation seen in moderate to severe psoriasis is associated with plaque destabilization and rupture that drives MI, and biologic treatment can reduce CV risk, according to a speaker.

A citrate-free formulation of Taltz injection for patients is now available following its FDA approval earlier this year, Eli Lilly and Company announced in a press release.

The FDA has approved ustekinumab for the treatment of children aged 6 years and older with active psoriatic arthritis, according to a Janssen press release.

The June 24 Supreme Court decision to overturn Roe vs. Wade continues to reverberate across all of health care, including rheumatology, dermatology and cancer treatment — and in this instance all three at once.

A treat-to-target strategy in which TNF inhibitors are tapered is non-inferior to a regimen without tapering for maintaining low disease activity in patients with psoriatic arthritis or axial spondyloarthritis, according to data.

Although there are plenty of drugs to treat psoriatic arthritis, and plenty of studies about those drugs individually, there are fewer trials examining strategies to treat patients who fail to respond to methotrexate in the first line.

Secukinumab 300 mg is a safe and effective first-line biologic for patients with psoriatic arthritis, according to data from a biologic-naïve population based in the United States.

Consuming specific dietary components such as vitamin D or omega-3 is “unlikely to influence the progression” of rheumatic and musculoskeletal diseases, according to a report of systemic reviews published in RMD Open.

A new artificial intelligence tool may improve diagnosis speed in patients with psoriatic arthritis, according to a press release summarizing data from the European Academy of Dermatology and Venereology’s Spring Symposium 2022.